{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9737","value":"0.632"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9076","value":"1.524"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"}],"units":"Participants"}],"description":"Clast is defined as the Last observed (quantifiable) plasma concentration (Clast), in units of ng/mL. Blood samples were collected to assess Clast.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","populationDescription":"The analysis was performed in PAS population, defined as all participants who provide at least one post-dose PK plasma sample. Here, number of participants analyzed refer to the number of participants evaluable for this outcome at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8","title":"Last Observed Plasma Concentration (Clast) of Panobinostat","type":"SECONDARY","unitOfMeasure":"ng/mL"}